Icatibant Stada (Icatibant)

Icatibant is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The dose of Icatibant Stada is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The medication is administered as a subcutaneous injection, and the exact regimen should follow the prescriber’s instructions.

Safety of icatibant in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑inhibitor concentrates replace the deficient protein. Icatibant provides a rapid, targeted approach to block bradykinin‑mediated swelling, while C1‑inhibitor products work upstream in the complement pathway.

Icatibant Stada should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the solution. If refrigeration is unavailable for a short period, it may be kept at controlled room temperature for up to 24 hours.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient, using the supplied pre‑filled syringe or autoinjector, following the prescriber’s dosing instructions.

Serious risks include anaphylaxis, airway angioedema that can compromise breathing, severe hypotension, and rare necrotic skin lesions at the injection site. Patients should be monitored for signs of allergic reaction and instructed to seek immediate medical care if severe symptoms develop.

Icatibant is contraindicated in patients with known hypersensitivity to icatibant or any of the formulation excipients. Caution is also advised for individuals taking ACE inhibitors, neprilysin inhibitors, or estrogen‑containing products, as these may increase the risk of angioedema.